A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single SQ Injection of Zalunfiban in Subjects With ST-elevation MI in the Pre-hospital Setting

This is a Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study. Subjects with STEMI will be enrolled in the ambulance if they meet all eligibility criteria. These subjects will be evaluated by (para)medics who transport the subjects to the participating hospitals in Europe and North America. Hospitals and ambulance services with experience in ambulance studies will be selected. Each subject will receive a single subcutaneous injection containing either Disaggpro(tm) zalunfiban Dose 1 (0.110 mg/kg) or Disaggpro(tm) zalunfiban Dose 2 (0.130 mg/kg) or placebo

开始日期2021-04-24

申办/合作机构

CeleCor Therapeutics, Inc.

NCT04284995

/ Completed临床2期

A Phase 2 Open Label Study to Assess the PK and PD Properties of a Single Subcutaneous Injection of RUC-4 in Patients With a ST-elevation Myocardial Infarction Presenting to the Cardiac Catheterization Lab With Planned Primary Coronary Angioplasty

RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration. This study is designed to extend the findings in CEL-01 to patients with ST-elevation myocardial Infarction (STEMI) presenting to the cardiac catheterization laboratory with planned coronary angioplasty.

开始日期2020-06-02

申办/合作机构

CeleCor Therapeutics, Inc.

[+2]

NCT03844191

/ Completed临床1期

A Randomized Phase 1 Dose-Escalation Study in Healthy Volunteers and Subjects on Aspirin With Stable Coronary Artery Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RUC-4

This study is designed to assess tolerability of the weight-adjusted dose of RUC-4 (mg/kg) required to achieve 80% or more inhibition of the initial slope of platelet aggregation to 20 µM ADP by Light Transmission Aggregometry (LTA) within 15 minutes of SC administration of RUC-4 with return toward baseline values within 4 hours in healthy volunteers and subjects on aspirin with stable coronary artery disease (CAD). In the Dose Expansion Part, VerifyNow PRUTest will be used to measure platelet aggregation in addition to LTA.
Since the goal of RUC-4 therapy is to achieve maximal antiplatelet therapy as rapidly as possible, first the tolerability of the weight-adjusted dose (mg/kg) that inhibits ADP-induced platelet aggregation by 80% or more in 5 of 6 healthy volunteers will be identified. A similar dose escalation will be subsequently performed in subjects with CAD who are taking aspirin. To facilitate administration using a single weight-adjusted (mg/kg) dose for a defined group of subjects weighing between 55 and 120 kg, the study will also evaluate the safety and biologic effect on platelet aggregation of the weight adjusted (mg/kg) dose when administered to subjects with weights at either end of this range.

开始日期2019-02-18

申办/合作机构

CeleCor Therapeutics, Inc.

[+3]

100 项与 Zalunfiban 相关的临床结果

登录后查看更多信息

100 项与 Zalunfiban 相关的转化医学

登录后查看更多信息

100 项与 Zalunfiban 相关的专利（医药）

登录后查看更多信息

项与 Zalunfiban 相关的文献（医药）

2026-11-01·AMERICAN HEART JOURNAL

The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI

Article

作者: Januzzi, James L ; Chi, Gerald ; van 't Hof, Arnoud W J ; Rikken, Sem A O F ; Verburg, Ashley ; Coller, Barry S ; Granger, Christopher B ; Gibson, C Michael ; Montalescot, Gilles ; Berg, Jurrien M Ten

BACKGROUND:

Among individuals with ST-segment elevation myocardial infarction (STEMI), a single subcutaneous injection of the short-acting glycoprotein IIb/IIIa receptor blocker antagonist zalunfiban at first medical contact significantly improved the primary outcome including clinical endpoints. The impact of zalunfiban on Myocardial Infarction (MI) size and association with downstream outcomes remains unclear.

METHODS:

In a prespecified analysis, we studied results among study participants treated with 2 doses of zalunfiban who had core laboratory measurements concentrations of hs-cTnT.

RESULTS:

More elevated hs-cTnT concentrations at presentation were associated with less resolution of ST deviation (P = .006) and more frequent Q wave development (P < .001). At coronary angiography more elevated hs-cTnT at presentation was associated with higher thrombus grade and worse epicardial and myocardial perfusion (all P < .05). In multivariable analyses, higher hs-cTnT concentrations at 24 hours were associated with greater adjusted risk for all-cause death (odds ratio [OR] 1.83 per log unit increase; P = .03), cardiovascular death (OR 1.83 per log unit increase; P = .03), heart failure (OR 2.74 per log unit increase; P < .001) or the composite of death and heart failure (P < .001) by 30 days. At 24 hours, those treated with zalunfiban had lower hs-cTnT compared to placebo (P = .04) and across multiples ≥ 10 to ≥ 1,000 times elevation, treatment with zalunfiban resulted in smaller hs-cTnT determined MI size.

CONCLUSIONS:

Among patients with STEMI, more elevated concentrations of hs-cTnT are associated with worse measures of reperfusion and higher-risk for short-term death or heart failure. A single dose of zalunfiban at first medical contact reduced MI size.

TRIAL REGISTRATION:

A phase 3 study of zalunfiban in subjects with ST-elevation MI (CELEBRATE); NCT04825743.

2026-09-01·AMERICAN JOURNAL OF CARDIOLOGY

Efficacy and Safety of Zalunfiban by Creatinine Clearance Among Patients with ST-Elevation Myocardial Infarction: Analysis from the CELEBRATE Trial

Article

作者: Rikken, Sem A O F ; Coller, Barry S ; Chi, Gerald ; Ten Berg, Jurrien M ; Verburg, Ashley ; Januzzi, James L ; Montalescot, Gilles ; van 't Hof, Arnoud W J ; Gibson, C Michael ; Granger, Christopher B

Renal impairment portends higher rates of clinical events and bleeding among patients with ST-segment elevation myocardial infarction (STEMI). Zalunfiban is a novel, subcutaneous glycoprotein IIb/IIIa inhibitor designed for prehospital administration. This post hoc analysis of the CELEBRATE trial evaluated the efficacy and safety of zalunfiban in STEMI patients across different levels of renal function. A total of 2,154 patients were categorized by baseline creatinine clearance (CrCl) levels. The primary efficacy endpoint was a 30-day major adverse composite clinical endpoint. The primary safety endpoint was Global Use of Strategies to Open Occluded Coronary Arteries severe or life-threatening bleeding at 30 days. Among patients with CrCl ≥ 30 to <60 ml/min, treatment with zalunfiban was associated with lower odds of the composite outcome (adjusted odds ratio 0.46, 95% confidence interval 0.23 to 0.94, p = 0.03). The treatment effect was not significantly modified by CrCl (p for interaction = 0.25). In addition, there were no significant differences in severe or life-threatening bleeding across all CrCl categories. Zalunfiban was associated with higher rates of mild-to-moderate bleeding among patients with CrCl ≥ 90 ml/min and those with ≥60 to <90 ml/min. A single subcutaneous dose of zalunfiban administered at first medical contact was not associated with an increased risk of major bleeding across the spectrum of renal function. In conclusion, although a signal for greater clinical benefit was observed among STEMI patients with CrCl ≥ 30 to <60 ml/min, there was no significant interaction by renal function, and these findings should be considered exploratory. A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI (CELEBRATE); ClinicalTrials.gov identifier: NCT04825743.

2026-05-01·Cardiology in Review

Zalunfiban: A Review of Current Knowledge and Future Applications of an Innovative Antiplatelet Agent

Review

作者: Sharma, Pritika ; Aronow, Wilbert S. ; Frishman, William H. ; Veasaw, Kassidy

Zalunfiban is a novel glycoprotein IIb/IIIa inhibitor currently being tested for its use in the prehospital setting for antiplatelet effect in patients with ST-elevation myocardial infarction. It has shown to be safe and effective in both phase 1 and phase 2 trials and is under investigation in phase 3 trials. In this review, we discuss zalunfiban in detail, including its mechanism of action, adverse effects, current recommendations for use, and ongoing trials.

项与 Zalunfiban 相关的新闻（医药）

2026-09-30

·PRNewswire

FDA ACCEPTS NEW DRUG APPLICATION FOR CELECOR'S INVESTIGATIONAL HEART-ATTACK DRUG

Agency assigns zalunfiban (Disaggpro TM ) a PDUFA target action date of June 18, 2027 DEL MAR, Calif., Sept. 30, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration has accepted CeleCor Therapeutics' New Drug Application (NDA) for zalunfiban (DisaggproTM) and assigned a target action date of June 18, 2027 under the Prescription Drug User Fee Act (PDUFA). Zalunfiban is an investigational, subcutaneously injected inhibitor of the platelet GPIIb/IIIa receptor designed to treat patients with STEMI (ST-segment elevation) heart attacks, the most severe form of heart attack. The priority in treating STEMI heart attacks is to open the coronary artery as soon as possible to prevent death or irreversible heart damage. "We look forward to working with the FDA as we seek approval for zalunfiban," said Rob Hillman, President and CEO of CeleCor. CeleCor announced completion of its NDA filing on June 24, following presentation in November 2025 of positive Phase 3 results from its CeleBrate study at the American Heart Association Scientific Sessions and simultaneous publication of the results in The New England Journal of Medicine Evidence. The multinational CeleBrate study found that rapid zalunfiban treatment for STEMI heart attacks at first point of medical contact reduced the risk of cardiovascular events over the 30 days following treatment. Zalunfiban is an investigational agent; it has not been approved for any use and its safety and efficacy have not been established . Zalunfiban is a novel small-molecule inhibitor of the platelet GPIIb/IIIa receptor and was specifically designed for subcutaneous injection for STEMI heart attacks. CeleCor Therapeutics was founded to improve the treatment of heart attacks at the first point of medical contact. For more information, visit our website and follow us on LinkedIn. CONTACT: Michael Moye, Chief Commercial Officer [email protected] SOURCE CeleCor Therapeutics, Inc. 21% more press release views with Request a Demo

申请上市AHA会议临床3期临床结果

2026-09-30

·BioSpace

FDA ACCEPTS NEW DRUG APPLICATION FOR CELECOR’S INVESTIGATIONAL HEART-ATTACK DRUG

Agency assigns zalunfiban (Disaggpro TM ) a PDUFA target action date of June 18, 2027 DEL MAR, Calif. , Sept. 30, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration has accepted CeleCor Therapeutics' New Drug Application (NDA) for zalunfiban (Disaggpro TM ) and assigned a target action date of June 18, 2027 under the Prescription Drug User Fee Act (PDUFA). Zalunfiban is an investigational, subcutaneously injected inhibitor of the platelet GPIIb/IIIa receptor designed to treat patients with STEMI (ST-segment elevation) heart attacks, the most severe form of heart attack. The priority in treating STEMI heart attacks is to open the coronary artery as soon as possible to prevent death or irreversible heart damage. "We look forward to working with the FDA as we seek approval for zalunfiban," said Rob Hillman, President and CEO of CeleCor. CeleCor announced completion of its NDA filing on June 24, following presentation in November 2025 of positive Phase 3 results from its CeleBrate study at the American Heart Association Scientific Sessions and simultaneous publication of the results in The New England Journal of Medicine Evidence . The multinational CeleBrate study found that rapid zalunfiban treatment for STEMI heart attacks at first point of medical contact reduced the risk of cardiovascular events over the 30 days following treatment. Zalunfiban is an investigational agent; it has not been approved for any use and its safety and efficacy have not been established . Zalunfiban is a novel small-molecule inhibitor of the platelet GPIIb/IIIa receptor and was specifically designed for subcutaneous injection for STEMI heart attacks. CeleCor Therapeutics was founded to improve the treatment of heart attacks at the first point of medical contact. For more information, visit our website and follow us on LinkedIn . CONTACT: Michael Moye , Chief Commercial Officer mmoye@celecor.com View original content to download multimedia: SOURCE CeleCor Therapeutics, Inc.

申请上市临床3期AHA会议临床结果

2026-07-17

·医心

冠心病优化抗栓治疗：现状与未来

抗栓治疗是冠心病急性期救治、经皮冠状动脉介入治疗（PCI）围手术期风险管理及长期二级预防的基石。近十年来，冠心病抗栓治疗领域的理念持续革新，技术不断突破。本文结合最新临床研究证据，对冠心病抗栓治疗的现状、挑战与未来发展方向展开述评，为临床实践与科学研究提供参考。 PART 01 新型抗栓药物研发抗栓药物创新的核心目标是开发疗效更优、出血风险更低、个体差异更小、使用更便捷的新型药物，弥补现有药物的临床短板。抗血小板药物研发仍以P2Y12受体抑制剂的迭代为主。坎格瑞洛（静脉注射制剂）和塞拉格雷（皮下注射制剂）丰富了P2Y12受体抑制剂在发病急性期和PCI围术期的应用场景，但对需求更为广阔的二级预防管理并无裨益。维卡格雷是我国自主研发的新型P2Y12受体抑制剂，具有独特的经肠道酯酶代谢途径，不依赖肝脏CYP2C19代谢。目前该药已完成Ⅰ、Ⅱ期临床研究，证实其在健康志愿者与冠心病患者中具有良好的药代动力学与药效学特征，可快速达到抑制抗血小板效果，不受基因多态性影响，个体间差异小，理论上兼具替格瑞洛的强效、快速起效以及氯吡格雷的安全性。正在开展的Ⅲ期临床研究聚焦急性冠脉综合征（ACS）与PCI术后人群，将维卡格雷与氯吡格雷进行头对头比较，若结果达到预期，将填补亚洲人群精准抗血小板治疗的空白，为临床提供更优选择。除P2Y12受体外，抗血小板药物研发还聚焦于凝血酶受体、血小板胶原受体、花生四烯酸通路等新靶点，但多数仍处于基础或早期临床研究阶段，尚未进入冠心病经典适应证研发路径，短期内难以改变临床格局。Zalunfiban是一种新型血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂，经皮下注射可快速起效，Ⅲ期CELEBRATE临床研究表明，ST段抬高心肌梗死（STEMI）患者于首次医疗接触时注射Zalunfiban与安慰剂相比可显著提高梗死相关动脉开通率，降低30d不良临床复合终点风险，不增加严重或致死性出血风险，但轻度或中度出血风险显著升高。Zalunfiban或可作为直接PCI前紧急抗血小板治疗过渡的新选择，但其能否降低硬终点事件风险尚有待证实。抗凝新药研发领域近年最受瞩目的焦点无疑是凝血因子XI抑制剂，其因参与内源性凝血通路、不增加出血风险而被视为非常有前景的新药。临床前研究证实，凝血因子XI单克隆抗体、反义寡核苷酸、小分子抑制剂可显著降低血栓形成风险，且不延长出血时间。然而，多项Ⅱb期及大型Ⅲ期临床研究结果令人失望。PACIFIC-AMI研究表明，急性心肌梗死患者在双联抗血小板治疗基础上加用小分子口服凝血因子XI抑制剂Asundexian，虽未增加出血风险，但疗效亦未能达到预期，使其用于ACS二级预防的Ⅲ期临床研究计划被迫终止。另一凝血因子XI抑制剂Milvexian用于ACS二级预防的Ⅲ期临床研究LIBREXIA-ACS研究，因中期分析结果表明不可能达到主要疗效终点而提前中止。凝血因子XI抑制剂受限于其仅参与血栓放大的靶点特性，对急性期血栓形成抑制作用有限，尤其在双联抗血小板治疗基础上，针对ACS血栓事件预防的获益有限，因此，对其在冠心病抗栓领域的应用需重新审视。 PART 02 抗栓治疗策略研究近年来，随着循证医学证据不断积累，冠心病抗栓治疗策略已从“更多更强”转向“优化平衡”，核心逻辑是在确保缺血获益的前提下，最大限度降低出血风险，提高患者的安全性与依从性，从而推动抗栓治疗从“一刀切”标准化方案向“一人一策”精准化模式转型。抗血小板治疗策略研究领域最突出的进展趋势之一是“做减法”。传统指南推荐ACS及PCI术后患者接受12个月标准双联抗血小板治疗，但长期双联抗血小板治疗显著增加出血风险，甚至导致停药后缺血风险反弹。近年来，多项大规模随机对照研究证实，对于ACS或PCI后患者（尤其是高出血风险者），1~3个月短期双联抗血小板治疗后转换至P2Y12受体抑制剂单药维持治疗，可在不增加缺血事件的同时，显著降低出血发生率。由中国学者主持的 ULTIMATE-DAPT、TWILIGHT-China等研究证实了这一策略在中国冠心病人群中同样安全、有效。此外，近年来自日本与韩国的长期随访研究证实了氯吡格雷单药长期治疗在减少PCI后患者血栓和出血事件风险方面优于经典的阿司匹林单药方案，为冠心病二级预防理念带来颠覆性的改变。上述证据共同推动了国内外指南的更新，同时深刻影响了临床实践。然而，需要强调的是，做减法的初衷是为了减少出血风险，并不适用于所有冠心病人群。对于出血风险不高且合并ACS、左主干病变、多支血管病变、支架内血栓、糖尿病等缺血高危人群，仍需评估缺血与出血风险，个体化决定双联抗血小板治疗时长，不可盲目缩短双联抗血小板治疗疗程。针对既往研究中代表性不足的特殊人群（如高龄、出血和缺血双高危、合并肾功能不全、无传统危险因素、冠心病合并心房颤动、寒地人群等），开展优化策略研究，填补证据空白，以完善个体化治疗体系，是近年抗血小板研究领域的另一大趋势。我国学者在这一领域进行了高水平的探索，如：OPT-BIRISK研究聚焦合并缺血和出血高危因素的ACS患者，发现延长氯吡格雷单药治疗与双联抗血小板治疗相比可显著降低出血及主要不良心脑事件风险，实现双重获益；OPTION研究入选肌钙蛋白阴性的PCI患者，证实以吲哚布芬为基础的双联抗血小板治疗较以常规阿司匹林为基础的双联抗血小板治疗方案可显著降低净不良临床事件风险；DACAB研究则表明，冠状动脉旁路移植术后患者接受以替格瑞洛为基础的双联抗血小板治疗，其长期疗效优于以常规氯吡格雷为基础的双联抗血小板治疗方案。此外，国内还有大量基于真实世界注册与大型队列的抗血小板治疗策略研究，与随机对照临床研究互为补充，进一步充实了特殊人群抗血小板治疗的临床证据。口服抗凝药在冠心病患者中的应用主要集中于需长期口服抗凝药治疗的非瓣膜心房颤动患者。近年来随着大量高水平随机对照临床研究结果的公布，口服抗凝药在ACS/PCI及稳定冠心病合并非瓣膜心房颤动患者中应用的最优原则已经明确，即PCI后短时间双联抗血小板治疗联合非维生素K拮抗剂口服抗凝药（NOAC）三联治疗后，转换为单一抗血小板药联合NOAC治疗6~12个月，其后稳定期患者应用NOAC单药长期治疗。另外，在PCI围术期胃肠外抗凝治疗策略研究领域，中国学者开创了新的局面。BRIGHT及BRIGHT-4研究证实了STEMI患者直接PCI围术期应用比伐芦定+高剂量术后延长注射方案较经典的肝素单药治疗方案显著降低了30d死亡和大出血风险；RIGHT研究表明，直接PCI后给予STEMI患者常规胃肠外抗凝治疗不增加出血风险；HELP-PCI研究证实，拟行直接PCI的STEMI患者在首次医疗接触时给予负荷剂量肝素治疗，较常规导管室给药可显著提高罪犯冠状动脉自发性再灌注比例且不增加出血风险。此外，一些真实世界注册研究及小样本随机对照研究探索了低剂量比伐芦定在择期PCI患者及合并肾功能不全的PCI患者中围术期应用的有效性和安全性。上述以BRIGHT系列为代表的研究已经成为国内外指南更新的重要依据。更加难能可贵的是，我们探索的步伐没有停止，比伐芦定用于高出血风险择期PCI患者的BRIGHT-HBR研究、早期肝素注射改善行直接PCI的STEMI患者1年临床硬终点的HELP PCI2研究等已经踏上征程。相信未来必将有更多的中国证据引领国内外指南和临床实践的变革。 PART 03 评估缺血与出血风险预测冠心病抗栓治疗的核心矛盾是缺血与出血风险的平衡，精准的缺血及出血风险预测是实现个体化抗栓的前提与基础。传统风险评估模型 GRACE、CRUSADE、PRECISE-DAPT、DAPT-ARC-HBR等，基于临床常规指标构建，操作简便，但存在预测精度有限、无法覆盖特殊人群、难以体现动态风险变化等不足。近年来，随着大数据、人工智能、机器学习技术的快速发展，冠心病抗栓风险预测迈入数字化、多维度、智能化新阶段。炎症反应贯穿动脉粥样硬化发生、发展、斑块破裂与血栓形成的全过程，很多炎症相关分子既是冠心病患者缺血事件的重要参与者，又是可检测的标志物。将炎症指标纳入风险预测模型，可弥补传统指标的不足，更早识别高危人群，为抗栓治疗强度调整提供依据。血脂水平及血脂谱的变化特征是冠心病残余风险预测的重要指标及干预靶点。此外，影像学（冠状动脉CT、血管内超声、光学相干断层成像等）和功能学（血流储备分数）指标直观地提供了病变局部的风险水平，成为越来越重要的风险预测因子。新一代风险预测模型将整合多维度数据，如患者基本临床特征、危险因素、合并症、实验室检查、PCI病变特征、用药史、基因多态性等，通过机器学习算法（随机森林、梯度提升树、神经网络等）进行深度挖掘与分析，显著提升风险预测的灵敏度与特异度。相较于传统模型，新型模型可捕捉非线性关系与交互作用，更精准地识别高危患者，为治疗方案选择提供量化支撑。尽管机器学习模型预测效能较好，但普遍存在“黑盒效应”，即模型可输出风险预测结果，但无法清晰解释各指标与风险之间的内在病理生理机制，缺乏生物学合理性，导致临床医生信任度低、推广困难。此外，多数模型存在事件数不足导致过拟合风险增高、缺少外部验证、缺乏指导临床实践的高水平证据等固有缺陷，难以直接应用于真实世界临床实践。未来风险预测研究应兼顾数据驱动与机制阐明，构建可解释、可验证、可落地的智能化模型。一方面，继续整合多组学数据（基因组、转录组、蛋白组、代谢组），提升预测精度；另一方面，深入解析危险因素与缺血/出血的分子机制，明确生物学通路，将机制研究与机器学习结合，使模型不仅“精准”而且“易懂”。同时，开展多中心、大样本真实世界验证，建立统一标准，以推动风险模型从科研工具转化为临床常规工具，实现“预测-分层-决策-监测”全流程闭环管理。 PART 04 总结与展望冠心病抗栓治疗历经数十年发展，已形成完善的诊疗体系，从传统药物到新型靶点探索，从标准化治疗到个体化策略优化，从单一指标评估到多维度数字化预测，整体朝着更安全、更精准、更高效、更贴合国人特点的方向迈进。同时，国内原创成果不断涌现，为全球指南与实践提供了关键支撑。未来，应进一步加速创新药物研发、完善特殊人群证据、整合多组学技术及新型生物标志物，借助人工智能、机器学习等优势构建可解释的风险模型、推广中国证据与指南、推进多学科交叉融合。随着创新研究持续深入、中国研发力量日益壮大，相信在不久的将来，冠心病抗栓治疗将实现新的突破，为冠心病患者带来更大获益。来源：李毅,韩雅玲. 冠心病优化抗栓治疗：现状与未来[J]. 中华心血管病杂志,2026,54(06)：613-617.DOI:10.3760/cma.j.cn112148-20260506-00286 往期推荐喜欢本文的人都在看获批临床试验！核心医疗全磁悬浮双心人工心脏闯入全心衰“无人区” 药物涂层球囊治疗新发小血管病变，会比DES更好吗？心闻5分钟丨健世科技三尖瓣置换系统LuX-Valve Plus取得CE认证；强生双能量消融获FDA批准上市 …… 心力衰竭的创新疗法：内脏神经消融心血管病诊疗状况，患者人数依旧庞大！中国心血管健康与疾病报告2025 2021年版心血管系统用药不良反应报告出炉，三类药上榜！这类药不良反应可能更多是心理作用基于人工智能的冠状动脉钙化评估进展免责声明：本文所提供内容仅供交流学习使用，不涉及商业盈利目的。如涉及版权问题，请联系本站管理员予以更改或删除。排版/编辑：医心编辑部

100 项与 Zalunfiban 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12051 D12163	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
ST段抬高心肌梗死	临床3期	美国	CeleCor Therapeutics, Inc.	2021-04-24
ST段抬高心肌梗死	临床3期	加拿大	CeleCor Therapeutics, Inc.	2021-04-24
ST段抬高心肌梗死	临床3期	捷克	CeleCor Therapeutics, Inc.	2021-04-24
ST段抬高心肌梗死	临床3期	法国	CeleCor Therapeutics, Inc.	2021-04-24
ST段抬高心肌梗死	临床3期	匈牙利	CeleCor Therapeutics, Inc.	2021-04-24
ST段抬高心肌梗死	临床3期	墨西哥	CeleCor Therapeutics, Inc.	2021-04-24
ST段抬高心肌梗死	临床3期	荷兰	CeleCor Therapeutics, Inc.	2021-04-24
ST段抬高心肌梗死	临床3期	罗马尼亚	CeleCor Therapeutics, Inc.	2021-04-24
冠状动脉疾病	临床2期	荷兰	CeleCor Therapeutics, Inc.	2020-06-02
冠心病	临床1期	美国	CeleCor Therapeutics, Inc.	2019-02-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04825743 (CELEBRATE, Pubmed \| NEJM Evid)	临床3期	ST段抬高心肌梗死	2,467	Zalunfiban 0.11 mg/kg	齋製淵製膚繭顧簾製繭(鑰構獵鏇鹽膚願願鏇顧) = 願構餘簾餘鏇衊積糧憲鬱夢壓築憲艱顧廠夢鹹 (範廠餘構壓衊廠壓蓋襯 ) 更多	积极	2025-12-23
				Placebo	齋製淵製膚繭顧簾製繭(鑰構獵鏇鹽膚願願鏇顧) = 積鹹簾淵憲鏇壓窪網廠鬱夢壓築憲艱顧廠夢鹹 (範廠餘構壓衊廠壓蓋襯 ) 更多
NCT04825743 (CeleBrate, PRNewswire) 人工标引	临床3期	ST段抬高心肌梗死	2,467	zalunfiban	範蓋鹽艱製壓鬱觸窪網(鹽齋觸壓淵淵觸觸積網) = positive 顧選齋顧網鹹製壓鹽窪 (壓齋築製鑰夢壓觸齋蓋 ) 更多	积极	2025-09-23
				Placebo
NCT04825743 (CELEBRATE, ESC2022)	临床2期	ST段抬高心肌梗死	27	Zalunfiban	齋醖獵築鑰艱壓醖遞窪(觸積願憲壓範餘鹽範廠) = 鏇艱積獵廠餘選鏇艱襯網顧壓膚構鹽鬱鑰繭觸 (鏇衊簾鬱齋願糧蓋鹽願 )	-	2022-03-18
ISTH2021	临床1期	ST段抬高心肌梗死	-	RUC-4 (Zalunfiban)	糧觸選積鏇夢獵簾鑰醖(鑰製憲範築憲網遞醖獵) = 願艱糧築網醖憲膚艱獵夢網淵衊醖窪餘築鬱範 (觸艱繭壓範鑰廠積顧築 )	-	2021-07-17